Tried-and-True or Something New?
Isn't it interesting that thiazide diuretics invented in 1958 are still the mainstays of hypertension therapy today?
Isn't it interesting that thiazide diuretics invented in 1958 are still the mainstays of hypertension therapy today?
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
The Wall Street Journal reports that new drug development offers hope for people with idiopathic pulmonary fibrosis, a rare, progressive fibrosing lung disorder that affects nearly 200,000 Americans, mostly middle-aged and older adults.
Fall is ahead and football season is here. This season only brings out my most competitive side. Winning is everything – in football and in medicine. To fail is objectionable, even cry-worthy, but it may also be motivating and humbling.
Uveitis is a common association of juvenile idiopathic arthritis (JIA) that has previously been characterized by poor visual prognosis with limited options for effective treatment.
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Behcet's disease is difficult to treat and often has an over-reliance on corticosteroid use. Alemtuzumab (previously known as Campath-1H) has been studed in patients with Behcet's.
In a study that compared seropositive (RF+, CCP+) and seronegative RA with healthy participants, the frequency of thyroid antibodies was assessed.
In reviewing submitted abstracts for the 2014 ACR meeting, I was surprised by several abstracts focusing on neutropenia in patients receiving rituximab.
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
I had just finished going over the prognosis and treatment plan with my newly diagnosed rheumatoid arthritis patient. I asked if she had any questions for me.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing form of interstitial pneumonia, with poor survival rates of nearly 50% at 3 years.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.